Recruiting

Testing a new medication to treat lung cancer

Plain-English translation of NCT07019675 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called to see if it can help treat lung cancer. Depending on your specific type of lung cancer and previous treatments, you may receive alone or combined with other medications. The study aims to understand how well this treatment works and what side effects patients experience.

Many patients with advanced lung cancer need better treatment options after their first treatment stops working. This medication is being studied to offer another path forward for patients whose cancer has progressed.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with non-small cell lung cancer or small cell lung cancer confirmed by a biopsy or cell sample
you have at least one tumor that can be measured on imaging scans
you are in good enough physical condition to tolerate treatment (ECOG score 0–1)
your doctor expects you to survive at least 12 weeks
your major organs (heart, kidneys, liver, lungs) are functioning well enough for the study

You likely don't qualify if…

you have heart disease that is not well controlled or causes symptoms
you have a history of lung inflammation or scarring that required steroid treatment, or you currently have lung inflammation
you are currently taking high-dose steroids (more than 10 mg per day of prednisone or equivalent) or other immune-suppressing medications
you have HIV, AIDS, or active syphilis infection
your doctor believes the study would be unsafe for you or interfere with your care

What participation looks like

You will visit the study center regularly to receive your medication and have your health monitored through blood tests and imaging scans. Depending on which group you are assigned to, you may take alone or combined with other medications. You will continue treatment until your cancer stops responding, side effects become too difficult to manage, or you and your doctor decide to stop—whichever comes first.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Trial locations(17 sites)

China

Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong

Cancer Hospital of Guangxi Medical University, Nanning, Guangxi

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hubei Cancer Hospital, Wuhan, Hubei

Renmin Hospital of Wuhan University, Wuhan, Hubei